CN103242294A - (S)-pantoprazole sodium dihydrate and preparation method thereof - Google Patents
(S)-pantoprazole sodium dihydrate and preparation method thereof Download PDFInfo
- Publication number
- CN103242294A CN103242294A CN2013100963279A CN201310096327A CN103242294A CN 103242294 A CN103242294 A CN 103242294A CN 2013100963279 A CN2013100963279 A CN 2013100963279A CN 201310096327 A CN201310096327 A CN 201310096327A CN 103242294 A CN103242294 A CN 103242294A
- Authority
- CN
- China
- Prior art keywords
- pantoprazole
- sodium dihydrate
- preparation
- pantoprazole sodium
- dihydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a (S)-pantoprazole sodium dihydrate the chemically general name of which is (S)-5-difluoromethoxy-2[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole sodium dihydrate. The invention also discloses a preparation method of the (S)-pantoprazole sodium dihydrate. The preparation method comprises the step of cooperatively salifying and crystallizing at a proper temperature by using dichloromethane as a solvent and an alkaline compound of metal sodium as a salifying reagent, thereby obtaining the (S)-pantoprazole sodium dihydrate. The preparation method is simple to operate and mild in reaction condition; the prepared (S)-pantoprazole sodium dihydrate is good in appearance and color, high in purity and stable in quality when stored at room temperature; and industrial production scale can recur.
Description
Technical field
The invention belongs to technical field of medicine synthesis, be specifically related to (S)-Pantoprazole Sodium dihydrate and preparation method thereof.
Background technology
General (the S)-5-difluoro-methoxy-2-[[(3 by name of its chemistry of compound (S)-pantoprazole, 4-dimethoxy-2--pyridine base) methyl] sulfinyl]-the 1H-benzoglyoxaline, (S)-pantoprazole and pharmaceutical salts thereof be described in CN1822835A.Pantoprazole is proton pump inhibitor, and by the final step that gastric acid inhibitory produces with two site covalent attachment of the H+-K+-ATP enzyme system of parietal cell, this effect is dose-dependently and the gastric acid secretion under basis and the stimulation state is all suppressed.(S)-pantoprazole can be used for the treatment of with gastric acid secretion disorderly diseases associated as acute hemorrhage of upper gastrointestinal tract and assistant-Emhorn syndromess such as gastroesophageal reflux, gastritis, AGML, stomach ulcer, plyability stomach ulcer, duodenitis, duodenal ulcers as proton pump inhibitor research as esomeprazole.Describe the effect that (S)-Pantoprazole Sodium has the gastric acid inhibitory secretion stronger than racemic modification Pantoprazole Sodium and R type isomer in the US Patent No. 5888535, good effect and toxic side effect are low, and bigger clinical treatment advantage is arranged.Saying in general sense, (S)-Pantoprazole Sodium can particularly be used for prevention and treatment and hydrochloric acid in gastric juice diseases associated among the people Mammals.
International Patent Application WO 94/24867 and WO94/25028 disclose compound (-)-and (+)-pantoprazole be used for the treatment of the purposes of human stomach trouble.
International Patent Application WO 2004/051511, WO2005/070426, US2006/0216346, WO2004013126(CN1671691) etc. the preparation method of (S)-Pantoprazole Sodium disclosed, adopt hexone and Virahol makes salt solvent, 30% sodium hydroxide solution is made salify reagent, prepared (the S)-pantoprazole sodium hydrate of cooling crystallization behind elder generation's salify, water content is between 2.0%～12.0%.
Chinese patent CN101597277 discloses and has made salify reagent, methyl alcohol with sodium methylate and make salt solvent elder generation salify, and through the intensification concentrated solvent, ether is made the method that the crystallization solvent carries out prepared (the S)-Pantoprazole Sodium of crystallization again.
Chinese patent CN101250181 discloses with sodium hydride and has made salify reagent, and tetrahydrofuran (THF) makes salt solvent, and ether is made the crystallization solvent, the method for the prepared of crystallization (S)-Pantoprazole Sodium behind the first salify.
Chinese patent application CN102382103 makes salt solvent with Virahol, and 1g/ml NaOH solution is made salify reagent, and t-butyl methyl ether is made the crystallization solvent, the method for the prepared of crystallization (S)-Pantoprazole Sodium behind the first salify.
Document " Shandong medicine thing " 2009,28(12): 745～746 disclose with butanone and have made salt solvent, and 30%NaOH solution is made salify reagent, and ether is made the crystallization solvent, the method for the prepared of crystallization (S)-Pantoprazole Sodium behind the first salify.
(S)-pantoprazole sodium hydrate of above-mentioned patent or the disclosed preparation of document is not a stable morphology, product has water absorbability, containing several hydrates exists jointly, at room temperature place easy moisture absorption or dehydration and lump, the product appearance color can slowly be deepened, deposit a weekly assembly and be transformed into reddish-brown, and form a large amount of degradation productions, analyzing reason should be to cause owing to not breaing up crystallization fully behind the salify.
International Patent Application WO 2006/064249 discloses with 2.1%NaOH solution and has made salify reagent, and acetone is made solvent, and ethyl acetate or isopropyl ether are made prepared (S)-pantoprazole sodium-hydrate and times semihydrate of crystallization solvent.
Chinese patent application CN101250180 discloses with sodium methylate, sodium ethylate, n-propyl alcohol sodium, sodium isopropylate and has made salify reagent, C
1～4Alkyl alcohol makes salt solvent, and ether is made the crystallization solvent, amorphous (the S)-Pantoprazole Sodium of the prepared of crystallization behind the first salify, and its moisture scope is 0.1%～1.9%.
Chinese patent application CN102584790 discloses with sodium hydroxide, sodium methylate, sodium ethylate, n-propyl alcohol sodium, sodium isopropylate and has made salify reagent, C
1～4Alkyl acetates makes salt solvent, and ether is made the crystallization solvent, the method for the prepared of crystallization (S)-pantoprazole sodium trihydrate behind the first salify, and its moisture scope is 12.1%～15.0%.
Disclosed preparation (S)-Pantoprazole Sodium does not have in the method for hydrate, monohydrate, times semihydrate, trihydrate in above-mentioned patent or the document, all are preparation methods of crystallization behind the first salify of employing: in one or both polar organic solvents, use the basic cpd salify of metal sodium salt earlier, use non-polar solvent (as ether, t-butyl methyl ether methyl ether, isopropyl ether) crystallization again.This method easily becomes oil when exist adding non-polar solvent, it is big to form the required nonpolar crystallization solvent load in oil back, simultaneously because material viscosity is strong, easily adhere to conversion unit and stirring rake, crystallization fully, gained sodium salt viscosity is strong, is unfavorable for industrial amplification production.
Summary of the invention
For overcoming above-mentioned technological deficiency, the inventor has carried out big quantity research to salify and the crystallization technology of (S)-pantoprazole, and the comparison by preparation technology, against expectation find: be solvent with the methylene dichloride, under cold condition collaborative carry out salify and crystallization after, can obtain (S)-Pantoprazole Sodium dihydrate of purity height and stable in properties through simple processing, and be suitable for industrial amplification production, therefore propose the present invention.
It is stronger that one of purpose of the present invention is to disclose a kind of stability, (S)-Pantoprazole Sodium dihydrate of high-purity crystallized attitude.
Two of purpose of the present invention also discloses the preparation method of above-mentioned (S)-Pantoprazole Sodium dihydrate.
(S)-Pantoprazole Sodium dihydrate disclosed by the invention, general (the S)-5-difluoro-methoxy-2[[(3 by name of its chemistry, 4-dimethoxy-2-pyridyl) methyl] sulfinyl]-1H-benzoglyoxaline sodium dihydrate, structural formula is
Described (S)-Pantoprazole Sodium dihydrate is crystal form, and its contained humidity is 8.0%～10.0%.
The X-ray powder diffraction figure of described (S)-Pantoprazole Sodium dihydrate has 6.1 ± 0.1, and 10.0 ± 0.1,11.5 ± 0.1,11.9 ± 0.1,12.1 ± 0.1,13.8 ± 0.1,14.5 ± 0.1,15.0 ± 0.1,15.4 ± 0.1,17.0 ± 0.1,17.9 ± 0.1,18.2 ± 0.1,19.5 ± 0.1,20.4 ± 0.1,20.7 ± 0.1,21.2 ± 0.1,22.9 ± 0.1,24.7 ± 0.1,25.3 ± 0.1,25.8 ± 0.1,26.2 ± 0.1,26.6 ± 0.1,27.7 ± 0.1,28.6 ± 0.1,29.4 ± 0.1,30.0 ± 0.1,30.5 ± 0.1,31.0 the diffraction peak at ± 0.1,32.1 ± 0.1,36.9 ± 0.1 2 θ angles.
The preparation method of (S)-Pantoprazole Sodium dihydrate disclosed by the invention comprises the steps:
(a) high antimer selectivity (S)-pantoprazole and methylene dichloride are mixed reflux dissolving, activated carbon decolorizing after-filtration;
(b) basic cpd that stream adds sodium Metal 99.5 in the filtrate reacts collaborative salify and the crystallization of carrying out;
(c) cool growing the grain;
(d) the growing the grain mother liquor with step (c) filters the filter cake eluent methylene chloride;
(e) with the filter cake vacuum-drying after the drip washing, obtain (S)-Pantoprazole Sodium dihydrate.
The basic cpd of described sodium Metal 99.5 is selected from one or more in sodium hydroxide, sodium methylate and the sodium ethylate, its add-on with (S)-mol ratio of pantoprazole is 0.9～1.2: 1.
The basic cpd of described sodium Metal 99.5 is the aqueous solution or alcoholic solution form, and the mass percent concentration of its solution is 1.0%～60.0%.
The basic cpd of described sodium Metal 99.5 is aqueous solution form, and its mass percent concentration is 30.0%; Or the basic cpd of described sodium Metal 99.5 is the alcoholic solution form, and its mass percent concentration is 10.0%.
The temperature of salify and crystallization is 0～40 ℃ in the described step (b), and the temperature of growing the grain is 0～10 ℃ in the described step (c).
The temperature of salify and crystallization is 20～30 ℃ in the described step (b), and when salify and recrystallization temperature were chosen as 24 ℃, the crystallization effect was best.
Vacuum drying temperature is 20～50 ℃ in the described step (e), and be 6～8h time of drying.
Beneficial effect of the present invention is:
(1) the invention discloses a kind of (S)-Pantoprazole Sodium dihydrate, in disclosed document and patent, all less than (S)-Pantoprazole Sodium dihydrate and crystal form thereof were carried out description, belong to a kind of novel (S)-pantoprazole sodium hydrate.
(2) use methylene dichloride to make the solvent of salify and crystallization among the preparation method of the present invention, replace and reported the reaction solvent that adopts low carbon chain ethers (ether, t-butyl methyl ether, isopropyl ether) in the technology, make that the productive rate of salify and crystallization is higher; The adding volume of methylene dichloride is 6～12 times of (S)-pantoprazole weight, and preferred 10 times, its productive rate is the highest.
(3) whole process salify and crystallization carry out simultaneously among the present invention, only adopt a kind of organic solvent of methylene dichloride, have solved that the oily matter of gained is not easy to break up problems such as crystallization behind the salify that crystallization technology is brought behind the prior art elder generation salify.
(4) the present invention under cold condition collaborative carry out carrying out growing the grain under salify and crystallization, the low temperature after, only need carrying out simple filtration, just to obtain appearance luster good, the purity height is at room temperature placed stay-in-grade (S)-Pantoprazole Sodium dihydrate.Low temperature is collaborative to carry out the stability that salify and crystallization technology are conducive to improve (S)-Pantoprazole Sodium dihydrate, having omitted simultaneously heats up behind the salify in the crystallization technology behind the first salify concentrates the step of organic solvent, has further simplified technological process, has improved the stability of bulk drug.
(5) preparation method of the present invention, can not occur in the prior art that crystallization technology oily matter of gained behind salify is not easy to break up crystallization behind the first salify, required crystallization solvent load is big, product dissolvent residual composition is many, product content is low, problems such as the easy moisture absorption of product and dehydration, be conducive to industrial amplification production, improved greatly production operation security and can be handling.
(6) preparation method of the present invention does not need through loaded down with trivial details purifying technique, the complete after-filtration reaction solution of salify and crystallization, a small amount of eluent methylene chloride filter cake, sample purity namely reaches more than 99.6%, optical purity reaches more than 99.8%, moisture stabilization is between 8.0%～10.0%, and mass yield is stabilized between 100.0%～110.0%.
(7) preparation method of the present invention is simple to operate, the productive rate height, the reaction conditions gentleness, it is the route of desirable suitable industrial amplification production preparation (S)-pantoprazole sodium hydrate, preparation method of the present invention has finished trial production in three batches, the full inspection of middle test agent meets the bulk drug quality standard, proves feasibility and good stability that this preparation method's production technique is amplified.
Description of drawings
Fig. 1 is the X-ray powder diffraction figure of preparation (S)-Pantoprazole Sodium dihydrate among the embodiment 4;
Fig. 2 is the X-ray powder diffraction figure of preparation (S)-Pantoprazole Sodium dihydrate among the embodiment 5;
Fig. 3 is the X-ray powder diffraction figure of preparation (S)-Pantoprazole Sodium dihydrate among the embodiment 6;
Fig. 4 is the HPLC figure of test agent related substance in (S)-Pantoprazole Sodium dihydrate;
Fig. 5 is the HPLC figure of the optical isomer of test agent in (S)-Pantoprazole Sodium dihydrate;
Fig. 6 is thermogravimetric analysis (TG) figure of test agent in (S)-Pantoprazole Sodium dihydrate;
Fig. 7 is test agent differential thermal analysis (DSC) figure in (S)-Pantoprazole Sodium dihydrate.
Embodiment
The present invention is described in detail below in conjunction with specific embodiment.
Embodiment 1:
10g high antimer selectivity (S)-pantoprazole is joined in three mouthfuls of reaction flasks of 250ml, add the 100ml methylene dichloride, dissolving fully under the temperature rising reflux, add activated carbon decolorizing 30min, filter, filtrate is stirred the dirty NaOH aqueous solution of 10.0% mass percent that adds (by NaOH and an amount of purified water configuration in 20～30 ℃, the mol ratio of NaOH and (S)-pantoprazole is 1:1), salify crystallization, stream add finish after, ice-water bath T=0～10 ℃ are stirred growing the grain 5h down, filter, 40～45 ℃ of vacuum-drying 6～8h get 10.1g off-white color (S)-Pantoprazole Sodium dihydrate, mass yield 101.0%.Moisture: 8.9%, chemical purity: 99.82%, single impurity≤0.1%; Optical purity=99.90%, dextrorotatory form=0.10%.
Embodiment 2:
10g high antimer selectivity (S)-pantoprazole is joined in three mouthfuls of reaction flasks of 250ml, add the 100ml methylene dichloride, dissolving fully under the temperature rising reflux, add activated carbon decolorizing 30min, filter, filtrate is stirred the dirty NaOH methanol solution that adds 20.0% mass percent (by NaOH and an amount of methyl alcohol configuration, the mol ratio of NaOH and (S)-pantoprazole is 1.2:1) salify crystallization in 20～30 ℃, finish the ice-water bath T=0～10 ℃ following growing the grain 5h that stirs in the 10min.Filter, 35～40 ℃ of vacuum-drying 6～8h get 10.4g off-white color (S)-Pantoprazole Sodium dihydrate, mass yield 104.0%.Moisture: 8.8%, chemical purity: 99.85%, single impurity≤0.1%; Optical purity=99.81%, dextrorotatory form=0.09%.
Embodiment 3:
10g high antimer selectivity (S)-pantoprazole is joined in three mouthfuls of reaction flasks of 250ml, add the 100ml methylene dichloride, dissolving adds activated carbon decolorizing 30min fully under the temperature rising reflux, filter, filtrate is stirred the dirty CH that adds 10.0% mass percent in 20～30 ℃
3The ONa methanol solution is (by CH
3ONa and an amount of methyl alcohol configuration, CH
3The mol ratio of ONa and (S)-pantoprazole is 0.9:1) the salify crystallization, finish in the 10min, ice-water bath T=0～10 ℃ are stirred growing the grain 5h down.Filter, 20～25 ℃ of vacuum-drying 6～8h get 10.1g off-white color (S)-Pantoprazole Sodium dihydrate, mass yield 101.0%.Moisture: 9.5%, chemical purity: 99.81%, single impurity≤0.03%; Optical purity=99.84%, dextrorotatory form=0.16%.
Embodiment 4:
1.0kg high antimer selectivity (S)-pantoprazole is joined in the 30L double-layer glass reaction kettle, add the 10L methylene dichloride, dissolving fully under the temperature rising reflux, add activated carbon decolorizing 30min, filter, filtrate is stirred the dirty NaOH aqueous solution (by 0.112kg NaOH and an amount of purified water configuration) the salify crystallization that adds 30.0% mass percent in 20～30 ℃, finishes in the 10min, and ice-water bath T=0～10 ℃ are stirred growing the grain 5h down.Filter, 35～40 ℃ of vacuum-drying 6～8h get 1.06kg off-white color (S)-Pantoprazole Sodium dihydrate, mass yield 106.0%.Moisture: 8.7%, content: 99.6%, chemical purity: 99.96%, single impurity≤0.03%; Optical purity=99.93%, dextrorotatory form=0.07%.
Embodiment 5:
1.0kg high antimer selectivity (S)-pantoprazole is joined in the 30L double-layer glass reaction kettle, add the 10L methylene dichloride, dissolving fully under the temperature rising reflux, add activated carbon decolorizing 30min, filter, filtrate is stirred the dirty NaOH aqueous solution (by 0.114kg NaOH and an amount of purified water configuration) the salify crystallization that adds 30.0% mass percent in 20～30 ℃, finishes in the 10min, and ice-water bath T=0～10 ℃ are stirred growing the grain 5h down.Filter, 30～35 ℃ of vacuum-drying 6～8h get 1.03kg off-white color (S)-Pantoprazole Sodium dihydrate, mass yield 103.0%.Moisture: 9.5%, content: 100.0%, chemical purity: 99.94%, single impurity≤0.06%; Optical purity=99.87%, dextrorotatory form=0.03%.
Embodiment 6:
1.0kg high antimer selectivity (S)-pantoprazole is joined in the 30L double-layer glass reaction kettle, add the 12L methylene dichloride, dissolving fully under the temperature rising reflux, add activated carbon decolorizing 30min, filter, filtrate is stirred the dirty NaOH aqueous solution (by 0.113kg NaOH and an amount of purified water configuration) the salify crystallization that adds 30.0% mass percent in 20～30 ℃, finishes in the 10min, and ice-water bath T=0～10 ℃ are stirred growing the grain 5h down.Filter, 40～45 ℃ of vacuum-drying 6～8h get 1.05kg off-white color (S)-Pantoprazole Sodium dihydrate, mass yield 105.0%.Moisture: 9.5%, content: 99.4%, chemical purity: 99.84%, single impurity≤0.1%; Optical purity=99.81%, dextrorotatory form=0.19%.
Embodiment 7: the preparation of high antimer selectivity (S)-pantoprazole
The preparation of above-mentioned high antimer selectivity (S)-pantoprazole is according to the technology preparation of publication CN102603716: in the 50L double-layer glass reaction kettle with 0.673kg (1R, 2S)-1-amino-2-indanol is dissolved in the 10L acetonitrile, add 0.387kg titanium isopropylate (IV) under the whipped state, be cooled to 15 ℃, stirred 15 minutes, add 2.0kg pantoprazole thioether 5-difluoro-methoxy-2-[[(3 then, 4-dimethoxy-2-pyridyl)-and methyl] sulfenyl]-the 1H-benzoglyoxaline, slowly drip 1.55kg hydrogen phosphide cumene (content 〉=80.0%) then, continue reaction 3h, add 16L toluene in the reaction system, stir 10min, add 12.5% ammoniacal liquor (10L * 2) then and respectively stir 30min, separatory, merge the ammoniacal liquor layer, in ice-water bath, transfer pH to 7.0～8.0 with glacial acetic acid then, use ethyl acetate (10L * 3) extraction again, merge organic layer, steam ethyl acetate then, add 10L ethyl acetate room temperature making beating 2h, filter (the S)-pantoprazole episome crude product that obtains.
Refining: (S)-pantoprazole episome crude product that will obtain drips the 10L petroleum ether and stirring then with the acetic acid ethyl dissolution of 10L, filters, and vacuum-drying below 40 ℃ obtains 1.20～1.30kg high antimer selectivity (S)-pantoprazole behind the purifying.Molar yield: 60.0～60.5%.Chemical purity 〉=99.8%, single impurity≤0.1%, total assorted≤0.2%; Optical purity 〉=99.8%, dextrorotatory form≤0.2%, ee value 〉=99.6%.
Crystal water is analyzed:
Test agent among three batches of the embodiment 4-6 is carried out the crystal water analysis, have tangible weightless platform before and after in the TG collection of illustrative plates, in 60～90 ℃ of quick weight loss; In DSC, after 80 ℃, lose crystal water and a tangible endotherm(ic)peak occurs, show and contain crystal water in the specimen.
(S)-theoretical value of Pantoprazole Sodium dihydrate contained humidity is 8.2%, in conjunction with lab scale sample and middle test agent by the moisture in Ka Erfeixiushi method (K.F.) specimen and the moisture of thermal weight loss (TG) working sample, scope is all 8.0%～10.0%, show that crystal water contained in the sample is 2, and draft (S)-Pantoprazole Sodium dihydrate moisture standards and be 8.0%～10.0%, as shown in table 1.
Table 1 (S)-Pantoprazole Sodium dihydrate crystal water is analyzed
Pilot scale:
15.0kg high antimer selectivity (S)-pantoprazole is joined in the 500L enamel reaction still, add the 180.0kg methylene dichloride, dissolving fully under the temperature rising reflux, add 0.5kg activated carbon decolorizing 30min, reaction solution is filtered in D and the clean area 500L enamel reaction still through accurate filter, filtrate is stirred dirty collaborative salify and the crystallization of carrying out of the NaOH aqueous solution (1.7kg NaOH and the configuration of 4.0kg purified water) that adds 30.0% mass percent in 20～30 ℃, finish the ice-water bath T=0～10 ℃ following growing the grain 5h that stirs in the 10min.Filter, dry 6～8h gets 15.3kg off-white color (S)-Pantoprazole Sodium dihydrate, mass yield 102.0% in 30～40 ℃ of vacuum bipyramids.Moisture: 9.3%, content: 99.7%, chemical purity: 99.93%, single assorted≤0.04%; Optical purity=99.90%, dextrorotatory form=0.10%.Pilot product related substance and optical isomer are carried out the HPLC analysis respectively, pilot product is carried out thermogravimetric analysis and differential thermal analysis, shown in Fig. 4-7.
Above content be in conjunction with concrete preferred implementation to further describing that the present invention does, can not assert that concrete enforcement of the present invention is confined to these explanations.For the general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, can also make some simple deduction or replace, all should be considered as belonging to protection scope of the present invention.
Claims (10)
1. (S)-Pantoprazole Sodium dihydrate is characterized in that: general (the S)-5-difluoro-methoxy-2[[(3 by name of its chemistry, 4-dimethoxy-2-pyridyl) methyl] sulfinyl]-1H-benzoglyoxaline sodium dihydrate, structural formula is
2. (S)-Pantoprazole Sodium dihydrate as claimed in claim 1, it is characterized in that: described (S)-Pantoprazole Sodium dihydrate is crystal form, and its moisture content is 8.0%～10.0%.
3. (S)-Pantoprazole Sodium dihydrate as claimed in claim 1, it is characterized in that: the X-ray powder diffraction figure of described (S)-Pantoprazole Sodium dihydrate has 6.1 ± 0.1,10.0 ± 0.1,11.5 ± 0.1,11.9 ± 0.1,12.1 ± 0.1,13.8 ± 0.1,14.5 ± 0.1,15.0 ± 0.1,15.4 ± 0.1,17.0 ± 0.1,17.9 ± 0.1,18.2 ± 0.1,19.5 ± 0.1,20.4 ± 0.1,20.7 ± 0.1,21.2 ± 0.1,22.9 ± 0.1,24.7 ± 0.1,25.3 ± 0.1,25.8 ± 0.1,26.2 ± 0.1,26.6 ± 0.1,27.7 ± 0.1,28.6 ± 0.1,29.4 ± 0.1,30.0 ± 0.1,30.5 ± 0.1,31.0 ± 0.1,32.1 the diffraction peak at ± 0.1,36.9 ± 0.1 2 θ angles.
4. the preparation method of (S)-Pantoprazole Sodium dihydrate as claimed in claim 1 is characterized in that comprising the steps:
(a) high antimer selectivity (S)-pantoprazole and methylene dichloride are mixed reflux dissolving, activated carbon decolorizing after-filtration;
(b) basic cpd that stream adds sodium Metal 99.5 in the filtrate reacts collaborative salify and the crystallization of carrying out;
(c) cool growing the grain;
(d) the growing the grain mother liquor with step (c) filters the filter cake eluent methylene chloride;
(e) with the filter cake vacuum-drying after the drip washing, obtain (S)-Pantoprazole Sodium dihydrate.
5. the preparation method of (S)-Pantoprazole Sodium dihydrate as claimed in claim 4, it is characterized in that: the basic cpd of described sodium Metal 99.5 is selected from one or more in sodium hydroxide, sodium methylate and the sodium ethylate, its add-on with (S)-mol ratio of pantoprazole is 0.9～1.2: 1.
6. the preparation method of (S)-Pantoprazole Sodium dihydrate as claimed in claim 4, it is characterized in that: the basic cpd of described sodium Metal 99.5 is the aqueous solution or alcoholic solution form, and the mass percent concentration of its solution is 1.0%～60.0%.
7. the preparation method of (S)-Pantoprazole Sodium dihydrate as claimed in claim 6, it is characterized in that: the basic cpd of described sodium Metal 99.5 is aqueous solution form, its mass percent concentration is 30.0%; Or the basic cpd of described sodium Metal 99.5 is the alcoholic solution form, and its mass percent concentration is 10.0%.
8. the preparation method of (S)-Pantoprazole Sodium dihydrate as claimed in claim 4 is characterized in that: the temperature of salify and crystallization is 0～40 ℃ in the described step (b), and the temperature of growing the grain is 0～10 ℃ in the described step (c).
9. the preparation method of (S)-Pantoprazole Sodium dihydrate as claimed in claim 8 is characterized in that: the temperature of salify and crystallization is 20～30 ℃ in the described step (b).
10. the preparation method of (S)-Pantoprazole Sodium dihydrate as claimed in claim 4, it is characterized in that: vacuum drying temperature is 20～50 ℃ in the described step (e), be 6～8h time of drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100963279A CN103242294A (en) | 2013-03-23 | 2013-03-23 | (S)-pantoprazole sodium dihydrate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100963279A CN103242294A (en) | 2013-03-23 | 2013-03-23 | (S)-pantoprazole sodium dihydrate and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103242294A true CN103242294A (en) | 2013-08-14 |
Family
ID=48922199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100963279A Pending CN103242294A (en) | 2013-03-23 | 2013-03-23 | (S)-pantoprazole sodium dihydrate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103242294A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104856993A (en) * | 2015-05-26 | 2015-08-26 | 苗怡文 | Medical pantoprazole sodium freeze-dried powder injection composition for treating digestive system diseases |
| CN105481832A (en) * | 2016-01-19 | 2016-04-13 | 海南卫康制药(潜山)有限公司 | (S)-pantoprazole sodium tetrahydrate and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101343267A (en) * | 2008-06-23 | 2009-01-14 | 陕西新安医药科技有限公司 | Preparation method for optical pure Pantoprazole |
| CN101597277A (en) * | 2008-06-04 | 2009-12-09 | 山东新时代药业有限公司 | The new preparation process of S-pantoprazole and salt |
| CN102382103A (en) * | 2011-11-01 | 2012-03-21 | 陕西合成药业有限公司 | Method for preparing and purifying (L)-pantoprazole sodium |
| CN102603716A (en) * | 2012-03-31 | 2012-07-25 | 广东华南药业集团有限公司 | Method for preparing (S)-pantoprazole in high-enantioselectivity way |
| CN102863426A (en) * | 2012-09-21 | 2013-01-09 | 湖南赛隆药业有限公司 | Improved method for preparing (-)-pantoprazole sodium through Sharpless asymmetric epoxidation reaction |
-
2013
- 2013-03-23 CN CN2013100963279A patent/CN103242294A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101597277A (en) * | 2008-06-04 | 2009-12-09 | 山东新时代药业有限公司 | The new preparation process of S-pantoprazole and salt |
| CN101343267A (en) * | 2008-06-23 | 2009-01-14 | 陕西新安医药科技有限公司 | Preparation method for optical pure Pantoprazole |
| CN102382103A (en) * | 2011-11-01 | 2012-03-21 | 陕西合成药业有限公司 | Method for preparing and purifying (L)-pantoprazole sodium |
| CN102603716A (en) * | 2012-03-31 | 2012-07-25 | 广东华南药业集团有限公司 | Method for preparing (S)-pantoprazole in high-enantioselectivity way |
| CN102863426A (en) * | 2012-09-21 | 2013-01-09 | 湖南赛隆药业有限公司 | Improved method for preparing (-)-pantoprazole sodium through Sharpless asymmetric epoxidation reaction |
Non-Patent Citations (3)
| Title |
|---|
| RAJENDRA D. MAHALE, ET AL.: "Davis Oxaziridine-Mediated Asymmetric Synthesis of Proton Pump Inhibitors Using DBU Salt of Prochiral Sulfide", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》, vol. 14, no. 5, 5 August 2010 (2010-08-05), pages 1264 - 1268 * |
| 李谢等: "S-(-)-泮托拉唑钠的合成研究", 《齐鲁药事》, vol. 28, no. 12, 31 December 2009 (2009-12-31), pages 745 - 746 * |
| 陈卫东等: "左旋泮托拉唑钠的合成", 《中国医药工业杂志》, vol. 43, no. 11, 31 December 2012 (2012-12-31), pages 881 - 883 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104856993A (en) * | 2015-05-26 | 2015-08-26 | 苗怡文 | Medical pantoprazole sodium freeze-dried powder injection composition for treating digestive system diseases |
| CN105481832A (en) * | 2016-01-19 | 2016-04-13 | 海南卫康制药(潜山)有限公司 | (S)-pantoprazole sodium tetrahydrate and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106256824B (en) | Preparation method of high-purity delafloxacin meglumine salt | |
| CN104418841A (en) | Preparation methods of optically pure rabeprazole and sodium salt thereof | |
| CN103242294A (en) | (S)-pantoprazole sodium dihydrate and preparation method thereof | |
| CN106279175A (en) | A kind of preparation method of Ertapenem Sodium | |
| CN103254265A (en) | Abiraterone acetate trifluoroacetate, and preparation method and application thereof | |
| CN102241668B (en) | Esomprazole salt | |
| CN104327073B (en) | A kind of semi-synthetic production method of vinpocetine | |
| CN103664750A (en) | Synthetic method of prazole chloride | |
| CN104530006A (en) | Lansoprazole preparation method | |
| CN110041307A (en) | The preparation method of esomeprazole sulfide intermediate | |
| CN103012369B (en) | Lansoprazole N crystal form and preparation method and application thereof | |
| CN107879979A (en) | A kind of preparation method of Dexmedetomidine | |
| CN103664888A (en) | Preparation method of esomeprazole trihydrate | |
| CN103319417A (en) | Method for preparing triclabendazole sulfoxide | |
| CN102558048A (en) | Polycrystal substance of piperaquine phosphate and preparation method thereof | |
| CN102952119A (en) | Sodium rabeprazole preparation method | |
| CN107759609A (en) | A kind of purification process of asenapine | |
| CN103467355A (en) | Preparation method of indapamide | |
| CN111423412A (en) | Crystalline form of d-rabeprazole sodium anhydride | |
| US9834540B2 (en) | Omeprazole Sodium semihydrate and preparation method thereof | |
| CN112939941A (en) | Preparation method of lansoprazole | |
| CN105693694B (en) | A kind of refining methd of (S)-Pantoprazole | |
| CN102731265A (en) | Preparation method of high-purity propofol | |
| CN104119287B (en) | Novel Acrosin inhibitor of isoxazole and preparation method thereof | |
| CN116063235A (en) | Industrial refining method of omeprazole intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130814 |